MRNA Stock Recent News
MRNA LATEST HEADLINES
Moderna (NASDAQ:MRNA ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ET Company Participants Rose Loughlin - EVP of Research Lavina Talukdar - SVP, Head of IR Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone. My name is Gena Wang.
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market. The post Why Moderna Stock Has Surged 20% This Week Despite Mixed News appeared first on Investor's Business Daily.
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Insider buying signals a market shift for Moderna, Inc. after years of relentless sales, with CEO Stephane Bancel purchasing MRNA shares due to perceived undervaluation. Moderna cut revenue guidance for 2025 to $1.5 to $2.5 billion, though the biotech has a strong pipeline of 10 drugs targeting a $30 billion market. Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities.
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.
The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials. In preclinical studies, EVM16 demonstrated significant tumor growth inhibition in syngeneic mouse model, with repeated dosing showing favorable safety and tolerability.
A big legal victory across the Atlantic Ocean was the news propelling Moderna (MRNA 15.94%) stock to a significant price surge on Hump Day. The win by the company, best known as the producer of the Spikevax COVID vaccine, pushed its stock nearly 16% higher during the trading session.
Major U.S. equities indexes fluctuated on Wednesday before gaining momentum in the afternoon to close the session higher.